Acumen Pharmaceuticals, Inc. (ABOS) Tops Q3 EPS by 2c

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported Q3 EPS of ($0.24), $0.02 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Acumen Pharmaceuticals, Inc. (ABOS) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
• SAS CEO van der Werff emerges as frontrunner for Air Canada top job - Bloomberg